Tags

Type your tag names separated by a space and hit enter

Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
J Infect Dis. 2000 Mar; 181(3):1180-4.JI

Abstract

Aminoglycoside-resistance mechanisms were characterized in Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients during a recent clinical trial of inhaled tobramycin. Impermeability, in which bacteria have reduced susceptibility to all aminoglycosides, was the predominant mode of resistance in isolates obtained both before and after 6 months of cyclic treatment with tobramycin or placebo administered by aerosol. Enzymatic resistance mechanisms were found in fewer than 10% of resistant isolates. P. aeruginosa from individual patients could be grouped on the basis of genetic relatedness. When enzymatic resistance was involved, all isolates in a group had elevated tobramycin MICs. When impermeability occurred, MICs of a genotypic group varied from susceptible to resistant. These findings suggest that impermeability resistance occurs in only a fraction of the P. aeruginosa population in lungs of persons with CF and that this form of resistance arises by a process involving multiple small changes in MIC.

Authors+Show Affiliations

Department of Research Biology, PathoGenesis Corp., Seattle, WA 98119, USA. dmacleod@pathogenesis.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

10720551

Citation

MacLeod, D L., et al. "Aminoglycoside-resistance Mechanisms for Cystic Fibrosis Pseudomonas Aeruginosa Isolates Are Unchanged By Long-term, Intermittent, Inhaled Tobramycin Treatment." The Journal of Infectious Diseases, vol. 181, no. 3, 2000, pp. 1180-4.
MacLeod DL, Nelson LE, Shawar RM, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis. 2000;181(3):1180-4.
MacLeod, D. L., Nelson, L. E., Shawar, R. M., Lin, B. B., Lockwood, L. G., Dirk, J. E., Miller, G. H., Burns, J. L., & Garber, R. L. (2000). Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. The Journal of Infectious Diseases, 181(3), 1180-4.
MacLeod DL, et al. Aminoglycoside-resistance Mechanisms for Cystic Fibrosis Pseudomonas Aeruginosa Isolates Are Unchanged By Long-term, Intermittent, Inhaled Tobramycin Treatment. J Infect Dis. 2000;181(3):1180-4. PubMed PMID: 10720551.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. AU - MacLeod,D L, AU - Nelson,L E, AU - Shawar,R M, AU - Lin,B B, AU - Lockwood,L G, AU - Dirk,J E, AU - Miller,G H, AU - Burns,J L, AU - Garber,R L, PY - 2000/3/18/pubmed PY - 2000/4/29/medline PY - 2000/3/18/entrez SP - 1180 EP - 4 JF - The Journal of infectious diseases JO - J Infect Dis VL - 181 IS - 3 N2 - Aminoglycoside-resistance mechanisms were characterized in Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients during a recent clinical trial of inhaled tobramycin. Impermeability, in which bacteria have reduced susceptibility to all aminoglycosides, was the predominant mode of resistance in isolates obtained both before and after 6 months of cyclic treatment with tobramycin or placebo administered by aerosol. Enzymatic resistance mechanisms were found in fewer than 10% of resistant isolates. P. aeruginosa from individual patients could be grouped on the basis of genetic relatedness. When enzymatic resistance was involved, all isolates in a group had elevated tobramycin MICs. When impermeability occurred, MICs of a genotypic group varied from susceptible to resistant. These findings suggest that impermeability resistance occurs in only a fraction of the P. aeruginosa population in lungs of persons with CF and that this form of resistance arises by a process involving multiple small changes in MIC. SN - 0022-1899 UR - https://www.unboundmedicine.com/medline/citation/10720551/Aminoglycoside_resistance_mechanisms_for_cystic_fibrosis_Pseudomonas_aeruginosa_isolates_are_unchanged_by_long_term_intermittent_inhaled_tobramycin_treatment_ L2 - https://academic.oup.com/jid/article-lookup/doi/10.1086/315312 DB - PRIME DP - Unbound Medicine ER -